Acacia Research Corporation — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter filing; quarterly figures below are from the filing’s unaudited supplemental table. Amounts are in U.S. dollars.
Business context
Acacia invests in intellectual property and monetizes patent rights through licensing and, when needed, litigation. It reported more than 1,560 license agreements and approximately $1.6 billion in cumulative gross licensing revenue. In 2018, new management focused on monetizing existing portfolios, reducing costs, and rebuilding the portfolio pipeline while exploring adjacent opportunities. The company acquired no new patent portfolios in 2018.
Financial performance
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $131.5 million | $65.4 million |
| Operating loss | $24.8 million | $27.3 million |
| Net income (loss) attributable to Acacia | $(105.0) million | $22.2 million |
| Basic and diluted earnings (loss) per share | $(2.10) | $0.44 |
| Net cash provided by operating activities | $20.9 million | $13.0 million |
| Cash, cash equivalents and short-term investments | $165.5 million | $136.6 million |
| Working capital | $170.4 million | $130.1 million |
- Revenue more than doubled, primarily because average revenue per agreement rose to $11.0 million from $3.3 million, despite fewer agreements (12 versus 20). 2018 revenue included $14.5 million from patent portfolio sales and $3.5 million from other settlements.
- The 2018 net loss largely reflected $59.1 million of unrealized losses on the Veritone investment and a $19.1 million realized loss on Veritone share sales. In 2017, Veritone-related gains contributed to reported net income.
- Patent impairment charges were $28.2 million, compared with $2.2 million in 2017. Patent amortization was $27.1 million, up 22%; general and administrative expense fell 31% to $18.9 million, and patent litigation and licensing expense declined 51% to $8.9 million.
- Revenue less portfolio operations was a loss of $6.0 million; operating margin was approximately negative 18.9% and net margin approximately negative 79.9% (calculated from reported figures).
- Operating cash flow improved, but cash and cash equivalents alone declined to $128.8 million. Year-end short-term investments were about $36.7 million. Investing cash outflow was $24.1 million and financing cash outflow was $4.6 million.
- The balance sheet reports no borrowings; the filing does not provide a separate debt balance. Current liabilities were $31.0 million, including $22.7 million of royalties and contingent legal fees payable.
- For Q4 2018, revenue was $49.2 million and net loss attributable to Acacia was $11.4 million, versus Q4 2017 revenue of $3.5 million and net loss of $110.2 million. Quarterly results were highly variable.
Material changes and developments
- Three licensees generated 45%, 17%, and 17% of 2018 revenue, creating significant revenue concentration. Four licensees accounted for nearly all year-end receivables.
- Accounts receivable increased to $32.9 million from $0.2 million, while royalties and contingent legal fees payable increased to $22.7 million from $1.6 million. The company said receivables were scheduled for collection in the first half of 2019 and most related payables for payment through Q3 2019.
- Acacia sold 2.7 million Veritone shares for an average $7.07 per share and ended 2018 with 1.42 million shares and warrants, together valued at approximately $7.5 million. It invested an additional $6.0 million in Miso Robotics in 2018, bringing its ownership to about 30%.
- The company repurchased 1.19 million shares for $4.6 million under a $20 million authorization; the program expired February 28, 2019.
- Leadership and board changes occurred during 2018, including senior executive departures and appointment of a new Chief Intellectual Property Officer. Headcount reductions continued; the company had 13 full-time employees at year-end.
Outlook, risks and contingencies
- Management said cash and expected operating cash flows should meet requirements through at least March 2020. No quantitative revenue or earnings guidance was provided. Management described late-stage patent investment opportunities under consideration, but no 2018 portfolio acquisitions were completed.
- Results depend on the timing and outcomes of licensing agreements and patent litigation; management cautioned that revenue can fluctuate substantially and may be delayed. Two patent infringement cases had trial dates scheduled within the following 12 months, subject to court changes.
- Patent enforcement brings risks of adverse rulings, appeals, patent invalidation, legal-cost awards, sanctions and prolonged expense. The company recorded $28.2 million of patent impairments following reduced expected cash flows, adverse litigation outcomes and decisions to stop funding certain portfolios.
- The Celltrace dispute was in ICC arbitration; an evidentiary hearing concluded in February 2019, post-hearing briefing was scheduled to conclude in April 2019, and a decision was pending. Acacia denied the allegations. The filing also disclosed other ordinary-course claims and patent litigation.
- Acacia reported approximately $222.9 million of federal and $19.5 million of state NOL carryforwards, but maintained a full valuation allowance on net deferred tax assets. A tax-benefits preservation plan adopted in March 2019 seeks to reduce ownership-change risk that could limit use of tax attributes.
- Management and the auditor concluded internal controls over financial reporting were effective at year-end. The financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether the elevated 2018 revenue reflects repeatable licensing activity or nonrecurring portfolio sales and settlements, and how concentrated future revenue remains.
- Collections of the $32.9 million year-end receivables and payment timing for the $22.7 million of royalties and contingent legal fees payable.
- Current value and liquidity of the remaining Veritone and Miso Robotics investments, including any subsequent impairment or market-value changes.
- Progress and outcomes in pending patent cases and the Celltrace arbitration, including possible legal costs, sanctions or settlement payments.
- Whether management can rebuild the patent pipeline and generate sustainable returns while operating with a substantially reduced portfolio and 13 employees.
- The company’s actual liquidity needs and any developments after the stated runway assessment; the filing provides no formal operating forecast.